Atea Pharmaceuticals, Inc. (AVIR) Stock Chart - Revenue & Earnings | Quarter Chart

📊 Income Statement

Revenue by Product

Revenue by Geography

Revenue, Gross Profit, Operating and Net Income

RevenueGross ProfitOperating IncomeNet Income
0100K200K300K400K500K600K700K800KQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Margin (%)

Gross MarginOperating MarginNet Income Margin
0815223038455260Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Operating Expenses

Research And Development ExpensesGeneral And Administrative Expenses
08M15M22M30M38M45M52M60MQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025

EBITDA

EBITDA
-60M-52M-45M-37M-30M-22M-15M-7M1Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

EPS

Revenue Variation (%)

Revenue Variation
-200-175-150-125-100-74-49-241Q1 2025

Income Variation (%)

Gross Profit VariationOperating Income Variation
02581012151820Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Revenue YoY Variation (%)

Income YoY Variation (%)

Gross Profit YoY VariationOperating Income YoY Variation
048111519222630Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Price-to-Earning Ratio

P/E Ratio
-3-2-2-2-1-0001Q3 2024Q4 2024Q1 2025Q2 2025

Income Breakdown

Operating IncomeInterest IncomeTotal Other Income Expenses NetNet Income
02M5M8M10M12M15M18M20MQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Per Share Metrics

Revenue Per ShareNet Income Per ShareOperating Cash Flow Per Share
000001111Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Expense Ratios

Research And Ddevelopement To RevenueStock Based Compensation To Revenue
0255075100125150175200Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
💰 Cash Flow Statement

Operating Cash Flow

Free Cash Flow

Cash At End Of Period
025M50M75M100M125M150M175M200MQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Cash Flow to Debt Ratio

Net Cash Provided By Operating ActivitiesNet Cash Used Provided By Financing Activities
025K50K75K100K125K150K175K200KQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025
🏦 Balance Sheet
📈 Key Metrics